Published in

Taylor and Francis Group, OncoImmunology, 9(2), p. e26011, 2013

DOI: 10.4161/onci.26011

Links

Tools

Export citation

Search in Google Scholar

Monitoring NK cell activity in patients with hematological malignancies

Journal article published in 2013 by Sébastien Viel ORCID, Emily Charrier, Antoine Marçais ORCID, Jacques Bienvenu, Paul Rouzaire, Lionel Karlin, Gilles Salles, Thierry Walzer
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Natural killer (NK) cells are lymphocytes of the innate immune system that can recognize and kill various types of malignant cells. Monitoring the activity of peripheral NK cells in patients affected by hematological malignancies may provide prognostic information or unveil ongoing tumor-specific immune responses. Moreover, further insights into the biology of NK cells might also promote the development of novel strategies for stimulating their anticancer activity. Here, we review the main methods to monitor phenotypic and functional NK cell properties in cancer patients, focusing on individuals affected by multiple myeloma, a hematological malignancy currently treated with immunomodulatory drugs.